Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
Trial details
- Registry ID
- NCT05468736
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as NVX-CoV2373
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 YearsNCT05468736 | Novavax | Phase 2, Phase 3 | Completed | 2024-01-16Actual |
| A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2NCT04611802 | Novavax | Phase 3 | Completed | 2023-04-10Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |